Brief: Phaserx gets positive opinion for orphan drug designation for PRX-OTC from EMA
25/04/2017 13:30
April 25 (Reuters) - Phaserx Inc PZRX.O
* Phaserx receives positive opinion for orphan drug
designation for PRX-OTC from european medicines agency
Source text for Eikon: ID:nPn3SV31Qa
Further company coverage: PZRX.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on PZ Wind Down
See all newsBrief: Phaserx, Roivant Enter Into Asset Purchase Agreement
Brief: Phaserx Says Auction For Nearly All Of Co's Assets Was Held, But Did Not Conclude
Brief: Phaserx Revokes Proposed Distribution Record Date
Brief: PhaseRx Receives Decision From Nasdaq Hearings Panel For Continued Listing Of Shares
Brief: Phaserx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding